$311 Million is the total value of Endurant Capital Management LP's 88 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UHS | New | UNIVERSAL HLTH SVCS INCcl b | $11,835,000 | – | 95,100 | +100.0% | 3.80% | – |
| VWR | New | VWR CORP | $7,233,000 | – | 256,484 | +100.0% | 2.33% | – |
| ZTS | New | ZOETIS INCcl a | $4,040,000 | – | 75,700 | +100.0% | 1.30% | – |
| ELGX | New | ENDOLOGIX INC | $2,425,000 | – | 335,007 | +100.0% | 0.78% | – |
| KTWO | New | K2M GROUP HLDGS INC | $2,424,000 | – | 118,200 | +100.0% | 0.78% | – |
| HALO | New | HALOZYME THERAPEUTICS INC | $2,282,000 | – | 176,100 | +100.0% | 0.73% | – |
| MDT | New | MEDTRONIC PLC | $2,006,000 | – | 24,900 | +100.0% | 0.64% | – |
| ILMN | New | ILLUMINA INC | $1,826,000 | – | 10,700 | +100.0% | 0.59% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $1,755,000 | – | 88,300 | +100.0% | 0.56% | – |
| GILD | New | GILEAD SCIENCES INC | $1,494,000 | – | 22,000 | +100.0% | 0.48% | – |
| NLNK | New | NEWLINK GENETICS CORP | $1,433,000 | – | 59,444 | +100.0% | 0.46% | – |
| VREX | New | VAREX IMAGING CORP | $1,428,000 | – | 42,500 | +100.0% | 0.46% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $1,363,000 | – | 340,672 | +100.0% | 0.44% | – |
| DPLO | New | DIPLOMAT PHARMACY INC | $1,356,000 | – | 85,043 | +100.0% | 0.44% | – |
| CNMD | New | CONMED CORP | $1,204,000 | – | 27,100 | +100.0% | 0.39% | – |
| ZSAN | New | ZOSANO PHARMA CORP | $1,135,000 | – | 597,180 | +100.0% | 0.36% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $1,101,000 | – | 29,600 | +100.0% | 0.35% | – |
| PDCO | New | PATTERSON COMPANIES INC | $1,013,000 | – | 22,400 | +100.0% | 0.33% | – |
| TVTY | New | TIVITY HEALTH INC | $928,000 | – | 31,900 | +100.0% | 0.30% | – |
| KERX | New | KERYX BIOPHARMACEUTICALS INC | $875,000 | – | 142,100 | +100.0% | 0.28% | – |
| PRTA | New | PROTHENA CORP PLC | $815,000 | – | 14,600 | +100.0% | 0.26% | – |
| ARA | New | AMERICAN RENAL ASSOCIATES HO | $776,000 | – | 45,978 | +100.0% | 0.25% | – |
| ALDR | New | ALDER BIOPHARMACEUTICALS INC | $763,000 | – | 36,700 | +100.0% | 0.24% | – |
| HUM | New | HUMANA INC | $742,000 | – | 3,600 | +100.0% | 0.24% | – |
| PKI | New | PERKINELMER INC | $673,000 | – | 11,593 | +100.0% | 0.22% | – |
| INCR | New | INC RESH HLDGS INCcl a | $514,000 | – | 11,200 | +100.0% | 0.16% | – |
| RGNX | New | REGENXBIO INC | $479,000 | – | 24,800 | +100.0% | 0.15% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $448,000 | – | 5,100 | +100.0% | 0.14% | – |
| CRVS | New | CORVUS PHARMACEUTICALS INC | $282,000 | – | 13,600 | +100.0% | 0.09% | – |
| ANAB | New | ANAPTYSBIO INC | $258,000 | – | 9,300 | +100.0% | 0.08% | – |
| XBI | New | SPDR SERIES TRUSTs&p biotech | $243,000 | – | 3,500 | +100.0% | 0.08% | – |
| VRX | New | VALEANT PHARMACEUTICALS INTL | $221,000 | – | 20,000 | +100.0% | 0.07% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.